REGULATORY INTELLIGENCE
What Is the Regulatory Status of a Peptide?
“Peptide” describes a broad class of molecules—not a single regulatory category. Some peptide-based drug products are FDA-approved for specific uses. Others remain investigational, are available only in controlled research, have been discontinued, or are sold strictly for laboratory use.
Search the Peptides Made Clear regulatory tracker to see what has been authorized, what is still being studied, and what a status does—and does not—mean.
- Research
- Preclinical
- Clinical trials
- FDA review
- Approved use
- Post-market monitoring
FDA approval applies to a specific drug product, formulation, indication, population, and conditions of use. It does not automatically apply to every product containing a similarly named peptide.
Database totals by status
Search the Peptide Regulatory Tracker
Every record below is tied to a compound in the Peptides Made Clear directory. Statuses are published only when an authoritative regulatory source and a verification date exist; everything else is labeled as awaiting verification.
107 records
5-Amino-1MQ
Awaiting verificationStatus requires editorial verification. No documented regulatory record has been published for this compound yet.
Jurisdiction: United States0 authoritative sourcesLast verified: Not verifiedACE-031 (ramatercept)
DiscontinuedAlso known as ramatercept, ActRIIB-IgG1
ACE-031 was an investigational compound whose development was discontinued after trial safety findings; it was never FDA-approved.
Jurisdiction: United StatesPhase: Phase 1/Phase 21 authoritative sourceLast verified: September 11, 2026Adamax
Awaiting verificationStatus requires editorial verification. No documented regulatory record has been published for this compound yet.
Jurisdiction: United States0 authoritative sourcesLast verified: Not verifiedAdipotide
Awaiting verificationStatus requires editorial verification. No documented regulatory record has been published for this compound yet.
Jurisdiction: United States0 authoritative sourcesLast verified: Not verifiedAfamelanotide (Melanotan I)
FDA-approvedAlso known as Melanotan I, Scenesse
Afamelanotide is FDA-approved as the Scenesse implant for erythropoietic protoporphyria; “Melanotan I” material sold elsewhere is not that product.
Jurisdiction: United StatesApproved product: ScenesseApproved indication: Prevention of phototoxicity in adults with erythropoietic protoporphyria1 authoritative sourceLast verified: September 11, 2026AHK-Cu
Awaiting verificationStatus requires editorial verification. No documented regulatory record has been published for this compound yet.
Jurisdiction: United States0 authoritative sourcesLast verified: Not verifiedAICAR
Awaiting verificationStatus requires editorial verification. No documented regulatory record has been published for this compound yet.
Jurisdiction: United States0 authoritative sourcesLast verified: Not verifiedAlprostadil
FDA-approvedAlso known as Muse, Caverject
Alprostadil is FDA-approved in specific urology products for erectile dysfunction.
Jurisdiction: United StatesApproved product: MuseApproved indication: Erectile dysfunction, per labeling1 authoritative sourceLast verified: September 11, 2026AOD-9604
No approved drugAlso known as hGH fragment 176-191
No FDA-approved drug product containing AOD-9604 was identified, and no active US trial record was verified.
Jurisdiction: United States1 authoritative sourceLast verified: September 11, 2026ARA-290
Awaiting verificationStatus requires editorial verification. No documented regulatory record has been published for this compound yet.
Jurisdiction: United States0 authoritative sourcesLast verified: Not verifiedBotulinum toxin
Awaiting verificationStatus requires editorial verification. No documented regulatory record has been published for this compound yet.
Jurisdiction: United States0 authoritative sourcesLast verified: Not verifiedBPC + TB
Awaiting verificationAlso known as BPC, TB
Status requires editorial verification. No documented regulatory record has been published for this compound yet.
Jurisdiction: United States0 authoritative sourcesLast verified: Not verifiedBPC 157 + GHK-Cu + TB-500
Awaiting verificationAlso known as BPC 157, GHK-Cu, TB-500
Status requires editorial verification. No documented regulatory record has been published for this compound yet.
Jurisdiction: United States0 authoritative sourcesLast verified: Not verifiedBPC 157 + GHK-Cu + TB-500 + KPV
Awaiting verificationAlso known as BPC 157, GHK-Cu, TB-500, KPV
Status requires editorial verification. No documented regulatory record has been published for this compound yet.
Jurisdiction: United States0 authoritative sourcesLast verified: Not verifiedBPC- + TB-500(17-23) + GHK-Cu50mg + KPV10 mg
Awaiting verificationAlso known as BPC-, TB-500(17-23), GHK-Cu50mg, KPV10 mg
Status requires editorial verification. No documented regulatory record has been published for this compound yet.
Jurisdiction: United States0 authoritative sourcesLast verified: Not verifiedBPC-157
No approved drugAlso known as Body Protection Compound-157
No FDA-approved drug product containing BPC-157 was identified, and FDA has raised compounding safety concerns.
Jurisdiction: United States1 authoritative sourceLast verified: September 11, 2026BPC-157 + GHK-Cu50mg + TB-500(17-23)
Awaiting verificationAlso known as BPC-157, GHK-Cu50mg, TB-500(17-23)
Status requires editorial verification. No documented regulatory record has been published for this compound yet.
Jurisdiction: United States0 authoritative sourcesLast verified: Not verifiedBPC-157 + TB-500(17-23)
Awaiting verificationAlso known as BPC-157, TB-500(17-23)
Status requires editorial verification. No documented regulatory record has been published for this compound yet.
Jurisdiction: United States0 authoritative sourcesLast verified: Not verifiedBremelanotide (PT-141)
FDA-approvedAlso known as PT-141, Vyleesi
Bremelanotide is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Jurisdiction: United StatesApproved product: VyleesiApproved indication: Acquired, generalized hypoactive sexual desire disorder in premenopausal women1 authoritative sourceLast verified: September 11, 2026Bronchogen
Awaiting verificationStatus requires editorial verification. No documented regulatory record has been published for this compound yet.
Jurisdiction: United States0 authoritative sourcesLast verified: Not verified
Understanding Each Regulatory Status
FDA reviewed evidence for a specific drug product and determined that its benefits outweigh its known and potential risks for the intended population and approved conditions of use.
Approval does not automatically extend to other indications, formulations, doses, routes, manufacturers, or similarly named products.
The compound is being evaluated as a potential medical product but has not received FDA approval for general marketing.
Investigational status is not proof of safety or effectiveness.
At least one relevant human study is registered as active, recruiting, enrolling, or otherwise ongoing.
A ClinicalTrials.gov listing does not mean that the U.S. government evaluated, approved, or endorsed the intervention.
A product is represented as intended for laboratory research rather than human or veterinary use.
“Research use only” is not a medical authorization, quality certification, or pathway for personal use.
A sponsor stopped development of the compound or of a particular program.
Discontinuation may occur for scientific, safety, effectiveness, commercial, strategic, or undisclosed reasons.
FDA approval for a particular product or indication was formally withdrawn.
A withdrawal may be voluntary or initiated through a regulatory process. The documented reason is shown whenever it is available.
A licensed pharmacy or outsourcing facility may prepare a customized drug under applicable federal and state requirements.
Compounded drugs are not FDA-approved. FDA does not verify their safety, effectiveness, or quality before marketing in the same way it reviews approved drug products.
A licensed clinician uses an approved drug for a condition, population, route, or other circumstance not included in its approved labeling.
Off-label prescribing does not change the FDA-approved labeling or create a new approved indication.
One Peptide Can Have More Than One Status
- Compound
- Specific product
- Specific formulation and route
- Specific indication
- Specific population
- Regulatory decision
A peptide-based active ingredient can be approved in one product for one indication while remaining investigational or unapproved for another use.
Possible status combination
- Approved product for Condition A
- Off-label clinical use for Condition B
- Phase 2 investigation for Condition C
- Research-only material sold by unrelated vendors
These are four different regulatory contexts. They should never be collapsed into the statement “the peptide is FDA-approved.”
From Discovery to FDA Approval
STAGE 1
Discovery and laboratory research
What happens: Researchers identify a molecule, mechanism, or potential biological target.
What it means: The compound is not an approved treatment.
STAGE 2
Preclinical research
What happens: Laboratory and animal research evaluates biological activity, toxicity, and other characteristics.
What it means: Promising preclinical findings do not establish human safety or effectiveness.
STAGE 3
Investigational authorization
What happens: A sponsor may submit an Investigational New Drug application before certain studies in humans begin.
What it means: Permission to conduct clinical research is not marketing approval.
STAGE 4
Clinical trials
What happens: Human studies investigate safety, pharmacology, effectiveness, and benefit-risk questions.
What it means: A registered or completed trial does not guarantee approval.
STAGE 5
Regulatory review
What happens: FDA specialists evaluate clinical data, chemistry, manufacturing, proposed labeling, and benefit-risk information.
What it means: The application is under evaluation; approval has not yet been granted.
STAGE 6
Approval
What happens: FDA authorizes a particular drug product for defined conditions of use.
What it means: The approved label controls what was formally reviewed and authorized.
STAGE 7
Post-market monitoring
What happens: Safety information, manufacturing quality, labeling, and real-world use continue to be monitored.
What it means: Approval status and labeling can change when new evidence emerges.
FDA-Approved Does Not Mean Approved for Everything
Changing one part of this equation can place a use outside the approved labeling. That does not necessarily mean the use is prohibited, but it does mean it should not be represented as an FDA-approved use.
How to Check an FDA Label
- Search Drugs@FDA.
- Match the active ingredient.
- Match the manufacturer and product.
- Open the most recent label.
- Read Indications and Usage.
- Check route, formulation, population, warnings, and revision date.
Clinical Trial Status Is Not Regulatory Approval
| ClinicalTrials.gov record | FDA approval |
|---|---|
| Registers a research study | Authorizes marketing of a drug product |
| May include planned, recruiting, active, completed, suspended, or terminated studies | Reflects an FDA regulatory decision |
| Can include approved or unapproved interventions | Applies to a defined product and use |
| Does not prove study results | Is based on FDA review of submitted evidence |
| Does not mean government endorsement | Permits marketing under approved labeling |
Always check the trial’s actual recruitment status and last update date. A compound should never be described as “in clinical trials” based solely on an outdated or terminated record.
Compounded Is Not the Same as FDA-Approved
Compounding can serve legitimate patient needs under applicable law. However, a compounded preparation is not reviewed and approved by FDA in the same manner as an approved drug product.
FDA-approved product
- Reviewed through an FDA application
- Approved labeling
- Defined manufacturing controls
- FDA benefit-risk determination
503A compounding
- Generally patient-specific
- Based on a valid prescription
- Primarily overseen by state boards, with applicable federal requirements
- Not FDA-approved
503B outsourcing facility
- Subject to different federal conditions and oversight
- May compound certain sterile drugs
- Must meet applicable requirements
- Finished compounded drugs are not FDA-approved
Inclusion on a bulk-substances list is not FDA approval and must never be presented as one.
Where We Verify Regulatory Information
FDA compounding resources
Information concerning Sections 503A and 503B and applicable bulk-substance categories.
Visit sourceSponsor or manufacturer records
Used only as secondary confirmation and always identified as sponsor-provided information.
Source priority
- FDA databases and official regulatory documents
- ClinicalTrials.gov
- Federal Register
- Other national regulators
- Peer-reviewed publications
- Sponsor records
- Reputable secondary sources for context only
Vendor pages, wellness blogs, social-media posts, and AI summaries are never used as the sole source of a status.
Recent Regulatory Changes
- September 19, 2025·Elamipretide (SS-31)·United States
FDA granted accelerated approval to Forzinity (elamipretide) for Barth syndrome.
InvestigationalFDA-approvedAuthoritative sourceVerified September 11, 2026
Common Regulatory Misunderstandings
MYTH
“It is being studied in humans, so it is FDA-approved.”
FACT
Human research and FDA marketing approval are separate regulatory stages.
MYTH
“A doctor can prescribe it, so the proposed use must be approved.”
FACT
An approved drug may sometimes be prescribed off-label. This does not create an additional FDA-approved indication.
MYTH
“A compounded preparation is an FDA-approved generic.”
FACT
Compounded drugs are not FDA-approved drug products.
MYTH
“Research use only means it passed a research safety standard.”
FACT
The phrase describes intended use; it is not an FDA determination of safety, effectiveness, identity, sterility, or quality.
MYTH
“FDA-approved peptide” means every version is approved.
FACT
Approval applies to the specific product and conditions documented in its FDA record.
MYTH
“A favorable advisory committee vote means the substance is approved.”
FACT
Advisory recommendations are generally nonbinding and do not themselves constitute final agency approval.
Regulatory Questions to Ask
- Which exact product is being discussed?
- What is the active ingredient?
- Which agency issued the decision?
- In which country?
- Is the status current?
- Is there an application number?
- What indication was approved?
- Which population was evaluated?
- What formulation and route were approved?
- Is the use off-label?
- Is the preparation compounded?
- Is the compound merely registered in a clinical trial?
- Was development discontinued?
- Has the approval or indication been withdrawn?
- Is the claim supported by a direct regulatory source?
Frequently Asked Questions About Peptide Regulation
Are peptides FDA-approved?
Some peptide-based drug products are FDA-approved for specific indications. Many other peptides remain investigational, unapproved, discontinued, or restricted to research contexts.
What does FDA-approved mean?
It means FDA reviewed the submitted data for a particular drug product and determined that its benefits outweigh its known and potential risks for its approved conditions of use.
Does a clinical trial mean FDA approval?
No. A trial studies an intervention. Approval is a separate regulatory decision.
What does investigational mean?
It generally means a compound or use is under study and has not received FDA approval for general marketing in that context.
Are compounded peptides FDA-approved?
Compounded drug preparations are not FDA-approved. Their regulatory framework differs from the approval process for manufactured drug products.
What does research use only mean?
It indicates that a product is represented for laboratory research and not for human or veterinary use. It does not establish medical approval or safety.
Is off-label use illegal?
Licensed clinicians may prescribe approved drugs off-label in appropriate circumstances. However, the off-label use itself is not an additional FDA-approved indication.
Can a peptide be approved in another country but not in the United States?
Yes. Different regulatory authorities can reach different decisions or review products at different times.
What is a withdrawn approval?
It means authorization for a product or indication was formally removed. The record should identify the scope, date, and documented reason.
How often does Peptides Made Clear verify statuses?
Each record is re-checked against its primary source when that source changes and on the review date shown inside the record. The most recent verification in the database is September 11, 2026.
Related reading
Peptides A–Z
The full searchable directory
Peptide Basics
What peptides are and how they work
Evidence Explainers
How to read a study and what it shows
Reported Effects & Limits
What research reports, and what is unknown
Compare Peptides
Side-by-side research comparisons
Peptides Made Clear
Beginner-friendly educational guides
Editorial trust
- Maintained by
- Peptides Made Clear Editorial Team
- Published
- September 11, 2026
- Last page review
- September 11, 2026
- Latest database verification
- September 11, 2026
No individual regulatory reviewer is listed because none has been assigned to this page.
Report an outdated status
Submissions go to our editorial review queue. Nothing you send here is published automatically.
Peptides Made Clear provides educational information about peptide science, research, and regulation. Regulatory status can change and may differ by product, use, formulation, manufacturer, and jurisdiction. This page is not legal or medical advice and does not recommend the use of any compound.